Exact Mass: 802.3498984000001

Exact Mass Matches: 802.3498984000001

Found 47 metabolites which its exact mass value is equals to given mass value 802.3498984000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dermorphin

Dermorphin

C40H50N8O10 (802.364972)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain[1]. Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain[1]. Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain[1].

   

Dermorphin

2-amino-N-(1-{[1-({[(1-{2-[(1-carbamoyl-2-hydroxyethyl)carbamoyl]pyrrolidin-1-yl}-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl]methyl}carbamoyl)-2-phenylethyl]carbamoyl}ethyl)-3-(4-hydroxyphenyl)propanamide

C40H50N8O10 (802.364972)


   
   
   
   
   
   

2,2,2-Trihydroxy-5,5,5-tribenzyldiuvaretin

2"",2"",2"""-Trihydroxy-5",5"",5""-tribenzyldiuvaretin

C51H46O9 (802.3141666)


   

2,2,2-Trihydroxy-5,3,5-tribenzylisodiuvaretin

2"",2"",2"""-Trihydroxy-5",3"",5""-tribenzylisodiuvaretin

C51H46O9 (802.3141666)


   

(25S)-spirost-5-ene-7-keto-1beta,3beta-diol 1-O-alpha-L-rhamnopyranosyl-(1->2)-(4-O-sulfo)-alpha-L-arabinopyranoside|angudracanoside A

(25S)-spirost-5-ene-7-keto-1beta,3beta-diol 1-O-alpha-L-rhamnopyranosyl-(1->2)-(4-O-sulfo)-alpha-L-arabinopyranoside|angudracanoside A

C38H58O16S (802.3445388)


   

ruscogenin 1-O-alpha-L-rhamnopyranosyl(1->2)-4-O-sulfo-beta-D-fucopyranoside

ruscogenin 1-O-alpha-L-rhamnopyranosyl(1->2)-4-O-sulfo-beta-D-fucopyranoside

C39H62O15S (802.3809222)


   

rel-(1R,2R,3S,6R,7S,8S,10S,14R,15R,16S,17R,18S,19R,20R)-8-(acetyloxy)-16-[(1R)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-19,20-dihydroxy-7,12,15,17-tetramethyl-4-oxo-3-propanoyl-5,11,13,21-tetraoxaheptacyclo[10.8.1.1(14,17).0(1,10).0(2,7).0(10,15).0(14,19)]docos-18-yl 2-methylpropanoate|tabularisin O

rel-(1R,2R,3S,6R,7S,8S,10S,14R,15R,16S,17R,18S,19R,20R)-8-(acetyloxy)-16-[(1R)-1-(acetyloxy)-2-methoxy-2-oxoethyl]-6-(furan-3-yl)-19,20-dihydroxy-7,12,15,17-tetramethyl-4-oxo-3-propanoyl-5,11,13,21-tetraoxaheptacyclo[10.8.1.1(14,17).0(1,10).0(2,7).0(10,15).0(14,19)]docos-18-yl 2-methylpropanoate|tabularisin O

C40H50O17 (802.304785)


   

deistelianoside A|diosgenin 3-O-[3-O-sulfate-alpha-L-rhamnopyranosyl-(1->4)]-beta-D-glucopyranoside

deistelianoside A|diosgenin 3-O-[3-O-sulfate-alpha-L-rhamnopyranosyl-(1->4)]-beta-D-glucopyranoside

C39H62O15S (802.3809222)


   
   

trans-2-tridecanoyl tunicamycin

trans-2-tridecanoyl tunicamycin

C36H58N4O16 (802.3847628)


   
   
   
   

Atazanavir sulfate

Atazanavir sulfate

C38H54N6O11S (802.3571094)


D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

   

Trityl Olmesartan Medoxomil

Trityl Olmesartan Medoxomil

C48H46N6O6 (802.3478656)


   
   
   

(E)-3-[4-[(2S,3S,4S,5S)-5-[2-[(2S,3S,4R,5R,6S)-4,5-dimethoxy-3,6-dimethyloxan-2-yl]oxyacetyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyphenyl]-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-2-methylprop-2-enamide

(E)-3-[4-[(2S,3S,4S,5S)-5-[2-[(2S,3S,4R,5R,6S)-4,5-dimethoxy-3,6-dimethyloxan-2-yl]oxyacetyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyphenyl]-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-2-methylprop-2-enamide

C37H50N6O14 (802.338484)


   

(E)-N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-11-methyldodec-2-enamide

(E)-N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-11-methyldodec-2-enamide

C36H58N4O16 (802.3847628)


   

Reyataz

Reyataz

C38H54N6O11S (802.3571094)


D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

   

tunicamycin A0

tunicamycin A0

C36H58N4O16 (802.3847628)


A nucleoside that is one of the homologues in the mixture that is tunicamycin, characterised by an 11-methyldodec-2-enoyl fatty acyl substituent on the amino group of the tunicamine moiety.

   
   

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H62O12S (802.3961772)


   
   
   
   
   
   
   
   
   
   
   

[(2r,3s,4s,5r,6r)-4-hydroxy-2-(hydroxymethyl)-6-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy]-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid

[(2r,3s,4s,5r,6r)-4-hydroxy-2-(hydroxymethyl)-6-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy]-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid

C39H62O15S (802.3809222)


   

(1s,3r,4s,5r,6r,8r,10s,23r,24r,25r,26r)-5-(acetyloxy)-4,26-dihydroxy-6-methyl-17,20-dioxo-24-{[(2e)-3-phenylprop-2-enoyl]oxy}-10-propyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-25-yl (2e)-2-methylbut-2-enoate

(1s,3r,4s,5r,6r,8r,10s,23r,24r,25r,26r)-5-(acetyloxy)-4,26-dihydroxy-6-methyl-17,20-dioxo-24-{[(2e)-3-phenylprop-2-enoyl]oxy}-10-propyl-2,7,9,21,27-pentaoxatricyclo[21.3.1.0³,⁸]heptacosan-25-yl (2e)-2-methylbut-2-enoate

C42H58O15 (802.3775518)


   

(1s,2r,3r,5s,8r,9r,10r,11s,13s,16r)-2,9,11,16-tetrakis(acetyloxy)-3-(2-hydroxypropan-2-yl)-6,10-dimethyl-5-{[(2e)-3-phenylprop-2-enoyl]oxy}-14-oxatetracyclo[8.6.0.0³,⁷.0¹³,¹⁶]hexadec-6-en-8-yl benzoate

(1s,2r,3r,5s,8r,9r,10r,11s,13s,16r)-2,9,11,16-tetrakis(acetyloxy)-3-(2-hydroxypropan-2-yl)-6,10-dimethyl-5-{[(2e)-3-phenylprop-2-enoyl]oxy}-14-oxatetracyclo[8.6.0.0³,⁷.0¹³,¹⁶]hexadec-6-en-8-yl benzoate

C44H50O14 (802.32004)


   

[(3s,4r,5r,6s)-4-hydroxy-6-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-oneoxy]-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid

[(3s,4r,5r,6s)-4-hydroxy-6-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,14'r,16'r)-16'-hydroxy-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-oneoxy]-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl]oxidanesulfonic acid

C38H58O16S (802.3445388)